FSD Pharma (CNSX:HUGE)

FSD Pharma (CNSX:HUGE)


Share Price
$ 0.14
Change
0 (0.00 %)
Market Cap
$187.44 m
Proactive Investors - Run By Investors For Investors

FSD Pharma

FSD Pharma is a publicly traded company on the Canadian Securities Exchange under the symbol HUGE. The Company, through its wholly-owned subsidiary FV Pharma Inc., holds an ACMPR license to cultivate cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR). HUGE, made history on its first day of trading on the Canadian Securities Exchange (“CSE”), broke the all-time...

EPIC: HUGE
Market: CSE:HUGE
OTCMKTS:FSDDF
52-week High/Low: C$0.94 / C$0.12
Sector: Cannabis
Market Cap: $187.44 m
Website: fsdpharma.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of FSD Pharma


FSD Pharma Snapshot

FSD Pharma, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer under The Cannabis Act, having received its cultivation license on October 13, 2017 and its Sale for Medical Purposes license on April 18, 2019. FSD is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome. FSD has 25,000 square feet that is licensed at its Ontario facility and expansion is currently underway.

FSD’s R&D platform is focused on cannabinoids and their potential for widespread clinical applications. FSD has a strong interest in acquiring an R&D platform with the capability of producing synthetic cannabinoids and intends to create FDA approved medications that will be commercialized internationally.

The Cobourg Plant
FSD’s wholly-owned grow facility is the former Kraft food production plant in Cobourg, Ontario, approximately an hour’s drive from Toronto.

Growth
FSD is undergoing a stage-phased development. Once complete, the facility is expected to have over 3,800,000 sq. ft of capacity to support cultivation, processing and related ancillary businesses with production in excess of 400,000 kg of cannabis per year by 2025. The facility sits on a 70-acre parcel of land of which 30 acres are currently utilized and 40 acres are available for future development.

Optimal Environment
FSD is creating a state of the art indoor hydroponic facility, optimized for large-scale, medical-grade cannabis production.

Fully Equipped
The facility has an electrical sub-station on site, natural gas lines, multiple water-intakes, rail lines directly into the facility and 26 loading docks.

DR. RAZA BOKHARI
Executive Co-Chairman of the Board and CEO

Dr. Raza Bokhari joined the board of FSD Pharma in August 2018 and was named Executive Co-Chairman of the Board in December, Interim CEO in February 2019 and Permanent CEO in June 2019. Dr. Bokhari has been responsible for developing and leading FSD’s strategic vision into synthetic cannabinoid platforms.

Over the past two decades, Dr. Bokhari has developed outstanding expertise in aggregating and accelerating life sciences and healthcare services companies. An effective “change agent,” with several years of experience and expertise in start-up and turn-around businesses, he has a history of turning around financially struggling companies. Dr. Bokhari also frequently consults on due diligence projects for PE and VC funds focused in investing in life sciences/bio-tech and healthcare services companies.

Dr. Bokhari is also the Chairman & CEO of PCL, a global diagnostic provider of addiction screening and opioid prescription medication monitoring, including designer drugs and synthetic cannabinoids. He is also the managing partner of RBx Capital, LP and board member of Akers Biosciences (Nasdaq: AKER).

Dr. Bokhari holds a Doctor of Medicine degree from the University of Punjab, Rawalpindi Medical College, and an Executive MBA from Temple University, Fox School of Business & Management where he currently serves on the board. He is also the Vice Chairman of the World Affairs Council and a Trustee of the esteemed Foreign Policy Research Institute.

ANTHONY DURKACZ
Executive Co-Chairman of the Board and Founder

Anthony Durkacz is currently a Director and Executive Vice President at First Republic Capital Corporation, which he joined in January 2014. First Republic has acted as the exclusive agent of the company and has raised approximately $53 million of equity capital to date.

Previously, Mr. Durkacz was President of Capital Ideas Investor Relations and before that Director and CFO of Snipp Interactive Inc. (TSXV: SPN). He was instrumental in the financing and public listing of the mobile marketing company with operations in Canada, USA, Mexico and India.

Mr. Durkacz is also the owner and President of Fortius Research & Trading Corp., which provides financial and investor relations consulting services to micro and small cap companies in various sectors and develops investment strategies for high net worth individuals. He also served as COO and CFO of MKU Canada Inc. engaging in mergers and acquisitions globally, and from 2002 to 2006 he served as the CFO of Astris Energi Inc., a dually listed public company in the USA and Canada which was acquired by an international conglomerate.

He began his career at TD Securities on the capital markets trading floor. Mr. Durkacz holds an Honours Bachelor of Business Administration from Brock University with a major in Accounting and Finance.

ZEESHAN SAEED
President, Founder and Director

Zeeshan Saeed is President and Director of FSD Pharma. As co-founder, of FV Pharma, now wholly owned by FSD, he has been involved with the company from the earliest stages. Mr. Saeed provided consulting advice to FV Pharma and was instrumental for raising the initial seed capital. He played a key role in bringing together a team of professionals in the development of the Corporation business plan as well as bringing key relationships to the company.

Mr. Saeed has experience in international capital markets and has helped various startups with the process of raising initial funding and getting listed on various stock exchanges. Before entering capital markets, he was the founder and CEO of Platinum telecommunications Inc. Mr. Saeed grew the company to a stage at which it was taken over by a public company.

DONAL CARROLL, CPA
Interim Chief Financial Officer

Donal Carroll joined FSD Pharma as Chief Financial Officer in 2018.

An experienced business executive, he has 20 years of corporate finance leadership and public company experience, as well as deep expertise in syndicate investing both in equity and debt securities. Mr. Carroll is also Chief Financial Officer of World Class Extractions Inc. With a balance of prudent financing practices and unique insights, Mr. Carroll has successfully guided companies for expansion and growth.

Throughout his tenure with Danaher, Alberto Culver – now Unilever (NYSE:UL) and Cardinal Meats, he was instrumental in major restructuring activities, mergers and acquisitions and the implementations of new internal controls and ERP systems resulting in significant efficiencies through periods of substantial change and strong company growth. Mr. Carroll has been Independent Director of Bird River Resources Inc., since September 15, 2017.

He holds a CPA-CMA designation as well as a Bachelor of Commerce degree from University College Dublin (UCD).

DR. SARA MAY, PH.D.
President, FV Pharma Inc.

Dr. Sara May is a Ph.D. graduate with a multidisciplinary background in plant breeding and crop genetics with over ten years’ experience designing, implementing and managing large-scale projects in the field, lab and greenhouse. She has extensive work experience with all aspects of National, International, Provincial and Regional Legislative Acts and Regulations. Dr. May has deep domain expertise in the Medical Cannabis industry, which includes managing large scale operations, developing and implementing quality control and quality assurance methods and standard operating procedures and HACCP. Her prior experience is in the United States growing and producing high quality medical cannabis in California. She was responsible for cloning, up-keep, harvesting, processing and selling product into licensed dispensaries. Dr. May designed a specialized crop breeding program and successfully developed two new strains of cannabis.

Dr. May has co-authored ten peer-reviewed published manuscripts and is an active peer reviewer for national and international scientific journals.

DR. EDWARD BRENNAN, JR., M.D., FACS
President, FSD Pharma BioSciences Division

Dr. Edward J. Brennan, Jr., M.D., FACS has more than 25 years of experience in leadership roles at major pharmaceutical companies and clinical research organizations. He is an accomplished biopharmaceutical executive with a proven track record in FDA submissions and drug development.

Dr. Brennan has extensive experience in all phases of clinical development across multiple therapeutic areas. As a Medical Director with Wyeth-Ayerst Research and GlaxoSmithKline, he led teams through ten IND applications and advanced multiple compounds from pre-candidate selection (proof of concept) through clinical trial management and approval. At GSK, he was also responsible for coordinating all clinical activities for external partners within its Center of Excellence in External Drug Discovery. He next founded IndiPharm, a full-service global CRO, that was eventually acquired by private equity company, Velocity Fund Partners.

Dr. Brennan received his undergraduate Bachelor of Science Degree in Pharmacy from the Philadelphia College of Pharmacy and Science. He went on to study Medicine at the Royal College of Surgeons in Ireland before receiving his medical degree from the Temple University School of Medicine.

SANDY HUARD
Head of Communications and Investor Relations

Sandy Huard is a marketing and communications executive, senior strategist and consultant with over 21 years of marketing and sales experience leading national marketing teams, driving sales performance and launching national brands in the financial services industry.

Prior to joining FSD Pharma, she was Head of Marketing & Communications for FNF Canada, the Canadian subsidiary of the largest title insurer in North America. Prior to that, she was Senior Sales Advisor to executives and sales leaders at BMO Financial Group and was responsible for building sales capabilities and driving sales results in the branch network, the national customer contact center and across the national specialized sales teams. She was also Director of Marketing & Communications at Alterna Savings and Director and Head of Marketing & Communications at Computershare Trust Company of Canada.

Ms. Huard holds an MBA in Finance and Marketing from the Schulich School of Business, a Bachelor of Science Education from Brandon University and an Honors Bachelor of Science from McMaster University. She is a CTA Certified Sales Coach, a Certified Positive Psychology Coach and a Certified DiSC practitioner. Sandy is a published author and is fluent in French.

520 William Street
Cobourg, ON K9A 3A5
Canada
[email protected]
www.fsdpharma.com

[email protected]

Market Reports Including HUGE

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use